AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8786194 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone
Number of subjects: 5
Study 8786194 — intervention group
Group type: COMPARATOR
Intervention: Testosterone propionate
Number of subjects: 5
Study 8471406 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 8471406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2869849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20, 40, and 60 mg b.i.d.)
Number of subjects: 19
Study 2869849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (25, 50, and 100 mg b.i.d.)
Number of subjects: 19
Study 2869849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2869849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 19
Study 2869849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 19
Study 31981364 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 395
Study 31981364 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MTX treatment)
Number of subjects: 395
Study 31981364 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate exposure (ever use)
Number of subjects: 395
Study 31981364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-response association
Number of subjects: 395
Study 30315150 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) add-on therapy (2700 mg/day) for 6 months
Number of subjects: 0
Study 30315150 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 26921057 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole adjunctive treatment (5 mg/day for 8 weeks)
Number of subjects: 60
Study 26921057 — intervention group
Group type: COMPARATOR
Intervention: Non-adjunctive treatment (control group)
Number of subjects: 60
Study 26921057 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 60
Study 23417688 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat products (RF)
Number of subjects: 22
Study 23417688 — intervention group
Group type: COMPARATOR
Intervention: Normal-fat products (NF)
Number of subjects: 22
Study 23417688 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3-enriched reduced-fat products (n-3 RF)
Number of subjects: 22
Study 21974983 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS followed by task-oriented training
Number of subjects: 24
Study 21974983 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS followed by task-oriented training
Number of subjects: 24
Study 20560730 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily
Number of subjects: 31
Study 20560730 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 80 mg once daily
Number of subjects: 31
Study 18627322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day for 12 weeks)
Number of subjects: 60
Study 18627322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus atorvastatin
Number of subjects: 60
Study 17518401 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic surgery using the Acrobot hands-on robotic system
Number of subjects: 28
Study 17518401 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 28
Study 11832257 — intervention group
Group type: EXPERIMENTAL
Intervention: Idoxifene 5 mg per day
Number of subjects: 56
Study 11832257 — intervention group
Group type: EXPERIMENTAL
Intervention: Idoxifene 10 mg per day
Number of subjects: 56
Study 11832257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 10234895 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 13388
Study 10234895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13388
Study 7862181 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended treatment with rifampin plus isoniazid for 12 months
Number of subjects: 335
Study 7862181 — intervention group
Group type: COMPARATOR
Intervention: Placebo for the second 6 months
Number of subjects: 335
Study 7862181 — intervention group
Group type: COMPARATOR
Intervention: No further treatment after 6 months for HIV-seronegative patients
Number of subjects: 335
Study 1789059 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms octreotide sc
Number of subjects: 51
Study 1789059 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg bromocriptine po
Number of subjects: 51
Study 1789059 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both drugs
Number of subjects: 51
Study 1789059 — intervention group
Group type: COMPARATOR
Intervention: Placebo sc
Number of subjects: 51
Study 7193614 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (Anafranil) 10 mg daily, with an option to increase to 40 mg
Number of subjects: 20
Study 7193614 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (Anafranil) after crossover from placebo
Number of subjects: 20
Study 7193614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30268865 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal androgen (AndroGel; Besins Healthcare, Brussels, Belgium)
Number of subjects: 50
Study 30268865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28198147 — intervention group
Group type: EXPERIMENTAL
Intervention: %IHF
Number of subjects: 275
Study 28198147 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated liver enzymes, glycemic, lipid, and inflammatory biomarkers
Number of subjects: 275
Study 28198147 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides and chemerin
Number of subjects: 275
Study 28198147 — intervention group
Group type: EXPERIMENTAL
Intervention: WC, alanine-aminotransferase, triglycerides/high-density lipoprotein cholesterol, and homeostasis model assessment of insulin resistance
Number of subjects: 275
Study 26055051 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness program
Number of subjects: 125
Study 26055051 — intervention group
Group type: COMPARATOR
Intervention: Physical activity program
Number of subjects: 125
Study 26055051 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study 24237728 — intervention group
Group type: EXPERIMENTAL
Intervention: Open‐eyed group
Number of subjects: 40
Study 24237728 — intervention group
Group type: COMPARATOR
Intervention: Blindfolded group
Number of subjects: 40
Study 24237728 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 21266301 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine plus voucher incentives (FV)
Number of subjects: 145
Study 21266301 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine without vouchers (F)
Number of subjects: 145
Study 21266301 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus voucher incentives (PV)
Number of subjects: 145
Study 21266301 — intervention group
Group type: COMPARATOR
Intervention: Placebo without vouchers (P)
Number of subjects: 145
Study 19076137 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous training programme (35‐59% of heart rate maximum reserve) for 8 weeks, 45‐60 min per session
Number of subjects: 22
Study 19076137 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group (21 age‐matched hypertensives, mean age 64 years, sd 8.53)
Number of subjects: 22
Study 16952487 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose (100 microg) of diazepam
Number of subjects: 0
Study 16952487 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic dose (10 mg) of diazepam
Number of subjects: 0
Study 16952487 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose (100 microg) of midazolam
Number of subjects: 0
Study 16952487 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic dose (7.5 mg) of midazolam
Number of subjects: 0
Study 16952487 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose (100 microg) of ZK253
Number of subjects: 0
Study 16952487 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic dose (50 mg) of ZK253
Number of subjects: 0
Study 16952487 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose (100 microg) of warfarin
Number of subjects: 0
Study 16952487 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic dose (5 mg) of warfarin
Number of subjects: 0
Study 16952487 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose of erythromycin
Number of subjects: 0
Study 15307692 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea (Group A)
Number of subjects: 84
Study 15307692 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (Group B)
Number of subjects: 84
Study 15307692 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of insulin and Chinese medicine (Group C)
Number of subjects: 84
Study 11398518 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone therapy (duration not exceeding 3 months)
Number of subjects: 22
Study 11398518 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone therapy (duration 5 years on average)
Number of subjects: 22
Study 11398518 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone therapy
Number of subjects: 22
Study 9014951 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved vastus lateralis muscles (I-VL)
Number of subjects: 8
Study 9014951 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-involved vastus lateralis muscles (N-VL)
Number of subjects: 8
Study 9014951 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexor hallucis longus muscles on the involved side (I-FHL)
Number of subjects: 8
Study 9014951 — intervention group
Group type: COMPARATOR
Intervention: Vastus lateralis muscles of controls (C-VL)
Number of subjects: 8
Study 7687807 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (35 micrograms/h)
Number of subjects: 6
Study 7687807 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study 3706623 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.0 mg/kg metrifonate (2 doses)
Number of subjects: 132
Study 3706623 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg metrifonate (2 doses)
Number of subjects: 132
Study 3706623 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.0 mg/kg metrifonate (1 dose)
Number of subjects: 132
Study 3706623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 30892799 — intervention group
Group type: EXPERIMENTAL
Intervention: Office hysteroscopy without a speculum
Number of subjects: 0
Study 30892799 — intervention group
Group type: COMPARATOR
Intervention: Traditional office hysteroscopy with a speculum
Number of subjects: 0
Study 29528180 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-only adaptation of family-focused treatment (FFT) for 12-15 weeks
Number of subjects: 46
Study 29528180 — intervention group
Group type: COMPARATOR
Intervention: Standard health education for 8-12 sessions
Number of subjects: 46
Study 29528180 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-only adaptation of family-focused treatment (FFT)
Number of subjects: 46
Study 26771632 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid and betaine supplementation with wine
Number of subjects: 117
Study 26771632 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation with wine
Number of subjects: 117
Study 26771632 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 supplementation with wine
Number of subjects: 117
Study 26771632 — intervention group
Group type: COMPARATOR
Intervention: Wine-only group (control)
Number of subjects: 117
Study 24588066 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive emotion regulation group therapy (ERGT)
Number of subjects: 51
Study 24588066 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual only waitlist condition
Number of subjects: 51
Study 22387276 — intervention group
Group type: EXPERIMENTAL
Intervention: DCD-training (soccer training for 10 weeks)
Number of subjects: 51
Study 22387276 — intervention group
Group type: COMPARATOR
Intervention: DCD non-training
Number of subjects: 51
Study 22387276 — intervention group
Group type: COMPARATOR
Intervention: Typically developing (TD) children
Number of subjects: 51
Study 20737164 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-matched trains at 100 pulses delivered at 7.5, 15, 25, 30, 50, and 100 Hz
Number of subjects: 10
Study 20737164 — intervention group
Group type: EXPERIMENTAL
Intervention: Trains of varying pulse number (50, 100, and 200 pulses) at 30 and 50 Hz
Number of subjects: 10
Study 20737164 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest frequency train (100 Hz)
Number of subjects: 10
Study 20737164 — intervention group
Group type: EXPERIMENTAL
Intervention: Force-time integral produced by the stimulation train
Number of subjects: 10
Study 18936595 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint (OS) therapy used at nighttime and for 3 hours during daytime for 7 weeks
Number of subjects: 20
Study 18936595 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint (OS) therapy
Number of subjects: 20
Study 18936595 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stomatognathic intervention)
Number of subjects: 20
Study 16087791 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg twice daily for 1 week
Number of subjects: 0
Study 16087791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12585182 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) plus human chorionic gonadotropin and progesterone
Number of subjects: 23
Study 12585182 — intervention group
Group type: COMPARATOR
Intervention: Multi-vitamin only
Number of subjects: 23
Study 10352202 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic parenteral nutrition (IDPN) with amino acids (AAs)
Number of subjects: 19
Study 10352202 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic parenteral nutrition (IDPN) without amino acids (AAs)
Number of subjects: 19
Study 10352202 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic parenteral nutrition (IDPN) with all three components (AAs, dextrose, lipids)
Number of subjects: 19
Study 10352202 — intervention group
Group type: COMPARATOR
Intervention: IDPN withheld
Number of subjects: 19
Study 7488807 — intervention group
Group type: EXPERIMENTAL
Intervention: 25,000 IU of vitamin A
Number of subjects: 167
Study 7488807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 1779314 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved ORS (20 g maltodextrin, 4 g glycine, 4 g glycyl‐glycine)
Number of subjects: 101
Study 1779314 — intervention group
Group type: COMPARATOR
Intervention: Standard ORS (WHO formulation containing citrate)
Number of subjects: 101
Study 1779314 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved ORS
Number of subjects: 101
Study 1779314 — intervention group
Group type: COMPARATOR
Intervention: Standard ORS
Number of subjects: 101
Study 6755855 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin (BCG) adjuvant immunotherapy plus conventional therapy
Number of subjects: 42
Study 6755855 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 42
Study 6755855 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin (BCG) adjuvant immunotherapy
Number of subjects: 42
Study 30864254 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance exercise and nutritional supplementation (protein and vitamin D)
Number of subjects: 112
Study 30864254 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 112
Study 30864254 — intervention group
Group type: COMPARATOR
Intervention: Nutritional supplementation alone (protein and vitamin D)
Number of subjects: 112
Study 30864254 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study 28122783 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid treatment (0.8 mg daily)
Number of subjects: 20327
Study 28122783 — intervention group
Group type: COMPARATOR
Intervention: Enalapril alone (10 mg daily)
Number of subjects: 20327
Study 26904965 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 7112
Study 26904965 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal surgery
Number of subjects: 7112
Study 26904965 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe PONV
Number of subjects: 7112
Study 24299323 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole-Mg 40 mg once daily
Number of subjects: 578
Study 24299323 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 578
Study 22876396 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based (AB) 0.1% chlorhexidine
Number of subjects: 20
Study 22876396 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-free (AF) 0.12% chlorhexidine
Number of subjects: 20
Study 19647661 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle bevel position bevel up
Number of subjects: 50
Study 19647661 — intervention group
Group type: COMPARATOR
Intervention: Needle bevel position bevel down
Number of subjects: 50
Study 17699180 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16483490 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA (n = 77)
Number of subjects: 155
Study 16483490 — intervention group
Group type: COMPARATOR
Intervention: Zevodas (n = 78)
Number of subjects: 155
Study 16483490 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA (n = 77) in AML patients
Number of subjects: 155
Study 16483490 — intervention group
Group type: COMPARATOR
Intervention: Zevodas (n = 78) in AML patients
Number of subjects: 155
Study 16483490 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA (n = 77) in ALL patients
Number of subjects: 155
Study 16483490 — intervention group
Group type: COMPARATOR
Intervention: Zevodas (n = 78) in ALL patients
Number of subjects: 155
Study 16483490 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA and Zevodas
Number of subjects: 155
Study 12421192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 10 mg/kg given at conclusion of surgery and again 3 hours later
Number of subjects: 30
Study 12421192 — intervention group
Group type: COMPARATOR
Intervention: Non-TXA (control group)
Number of subjects: 30
Study 10510140 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg twice daily
Number of subjects: 38
Study 10510140 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg twice daily
Number of subjects: 38
Study 10510140 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1600 microg twice daily
Number of subjects: 38
Study 10510140 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (all doses)
Number of subjects: 38
Study 7717564 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia
Number of subjects: 18
Study 7717564 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 18
Study 7717564 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane and Isoflurane anesthesia
Number of subjects: 18
Study 1851688 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mmol of sodium/day diet
Number of subjects: 7
Study 1851688 — intervention group
Group type: COMPARATOR
Intervention: 20 mmol of sodium/day diet
Number of subjects: 7
Study 1851688 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 7
Study 7128221 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg/day
Number of subjects: 10
Study 7128221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29454369 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezocision (PG)
Number of subjects: 36
Study 29454369 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted flapless corticotomy (LG)
Number of subjects: 36
Study 29454369 — intervention group
Group type: COMPARATOR
Intervention: Control side (for both PG and LG)
Number of subjects: 36
Study 24469619 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 116
Study 24469619 — intervention group
Group type: COMPARATOR
Intervention: Open Repair (OR)
Number of subjects: 116
Study 21971628 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program of 16 sessions of 2.5 hours each over 4 months
Number of subjects: 69
Study 21971628 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 69
Study 20522079 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitex agnus castus (VAC, BNO 1095)
Number of subjects: 67
Study 20522079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 18672986 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% eucalyptus extract chewing gum for 12 weeks (90 mg/day)
Number of subjects: 97
Study 18672986 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% eucalyptus extract chewing gum for 12 weeks (60 mg/day)
Number of subjects: 97
Study 18672986 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum without eucalyptus extract for 12 weeks
Number of subjects: 97
Study 16551899 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone initial dose of 100 or 250 microg/kg
Number of subjects: 16
Study 16551899 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous IV infusion of milrinone at 0.5 microg x kg(‐1) x min(‐1)
Number of subjects: 16
Study 16551899 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative milrinone clearance
Number of subjects: 16
Study 16551899 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion rate of milrinone at 0.2 microg x kg(‐1) x min(‐1)
Number of subjects: 16
Study 14666758 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SI)
Number of subjects: 62
Study 14666758 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine treatment + SI
Number of subjects: 62
Study 14666758 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 62
Study 10700663 — intervention group
Group type: EXPERIMENTAL
Intervention: buspirone 0.14 mg/kg
Number of subjects: 14
Study 10700663 — intervention group
Group type: EXPERIMENTAL
Intervention: buspirone 0.28 mg/kg
Number of subjects: 14
Study 10700663 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14